Palvella Therapeutics, Inc. Legal Fees
Palvella Therapeutics, Inc. (PVLA) reported Legal Fees of $13.90 thousand for the 3-month period ending 2014-09-30, per its 10-Q filed 2014-11-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LegalFees · last filed 2014-11-13
- Palvella Therapeutics, Inc. legal fees for the quarter ending 2014-09-30 was $13.90K, a 141.74% increase year-over-year.
- Palvella Therapeutics, Inc. legal fees for the quarter ending 2014-06-30 was $5.75K.
- Palvella Therapeutics, Inc. legal fees for the quarter ending 2014-03-31 was $1.53K.
- Palvella Therapeutics, Inc. legal fees for the quarter ending 2013-12-31 was $2.16K.
- Palvella Therapeutics, Inc. legal fees for fiscal 2014 was $15.19K.
| Period end | Legal Fees 3 month | Legal Fees 6 month | Legal Fees 7 month | Legal Fees 9 month | Legal Fees 10 month | Legal Fees 12 month | Legal Fees 13 month | Legal Fees 16 month |
|---|---|---|---|---|---|---|---|---|
| 2014-09-30 | $13.90K 10-Q · filed 2014-11-13 | $19.65K derived: sum of 2 quarters · filed 2014-11-13 | $21.18K derived: sum of 3 quarters · filed 2014-11-13 | $23.34K derived: sum of 4 quarters · filed 2014-11-13 | $29.09K 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | $5.75K derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-12 | $7.28K derived: sum of 2 quarters · filed 2014-09-12 | $9.44K derived: sum of 3 quarters · filed 2014-09-12 | $15.19K 10-K · filed 2014-09-12 | $15.19K 10-K · filed 2014-09-12 | |||
| 2014-03-31 | $1.53K 10-Q · filed 2014-06-02 | $3.69K derived: sum of 2 quarters · filed 2014-06-02 | $9.44K 10-Q · filed 2014-06-02 | $9.44K 10-Q · filed 2014-06-02 | ||||
| 2013-12-31 | $2.16K 10-Q · filed 2014-05-14 | $7.91K 10-Q · filed 2014-05-14 | $7.91K 10-Q · filed 2014-05-14 | |||||
| 2013-09-30 | $5.75K 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |